Brusatol provokes a rapid and transient inhibition of Nrf2 signaling and sensitizes mammalian cells to chemical toxicity - Implications for therapeutic targeting of Nrf2

Free Radical Biology and Medicine

Volumn 78, Issue , 2015, Pages 202-212

  Olayanju, Adedamola ^a   Copple, Ian M ^a   Bryan, Holly K ^a   Edge, George T ^a   Sison, Rowena L ^a   Wong, Min Wei ^a   Lai, Zheng Quan ^b   Lin, Zhi Xiu ^b   Dunn, Karen ^a   Sanderson, Christopher M ^a   Alghanem, Ahmad F ^a   Cross, Michael J ^a   Ellis, Ewa C ^c   Ingelman Sundberg, Magnus ^d   Malik, Hassan Z ^e   Kitteringham, Neil R ^a   Goldring, Christopher E ^a   Park, B Kevin ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d KAROLINSKA INSTITUTE   (Sweden)

^e ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

Brusatol; Cell defense; Chemical stress; Free radicals; Hepatocyte; Keap1; Nrf2; Toxicity

Indexed keywords

1 CHLORO 2,4 DINITROBENZENE; 1,4 BENZOQUINONE DERIVATIVE; BRUSATOL; IODOACETAMIDE; KELCH LIKE ECH ASSOCIATED PROTEIN 1; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEASOME; PROTEIN KINASE B; STRESS ACTIVATED PROTEIN KINASE 1; TRANSCRIPTION FACTOR NRF2; MESSENGER RNA; QUASSINOID DERIVATIVE; SMALL INTERFERING RNA;

ANIMAL CELL; ARTICLE; AUTOPHAGY; CELL VIABILITY; CHEMICAL STRESS; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVATION; HEPATOMA CELL; HUMAN; HUMAN CELL; MAMMAL CELL; MOUSE; NONHUMAN; OXIDATIVE STRESS; PROTEIN DEGRADATION; SENSITIZATION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; BRUCEA; CARCINOMA, HEPATOCELLULAR; CELL CULTURE; CELL PROLIFERATION; CHEMISTRY; CYTOLOGY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; LIVER CELL; LIVER NEOPLASMS; METABOLISM; OXIDATION REDUCTION REACTION; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

MAMMALIA;

ANIMALS; APOPTOSIS; AUTOPHAGY; BLOTTING, WESTERN; BRUCEA; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; CELLS, CULTURED; GENE EXPRESSION REGULATION; HEPATOCYTES; HUMANS; LIVER NEOPLASMS; MICE; NF-E2-RELATED FACTOR 2; OXIDATION-REDUCTION; OXIDATIVE STRESS; QUASSINS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION;

EID: 84919663660     PISSN: 08915849     EISSN: 18734596     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2014.11.003     Document Type: Article

References (27)

1. H.K. Bryan, A. Olayanju, C.E. Goldring, and B.K. Park The Nrf2 cell defence pathway: Keap1-dependent and -independent mechanisms of regulation Biochem. Pharmacol. 85 2013 705 717
2. K. Itoh, N. Wakabayashi, Y. Katoh, T. Ishii, K. Igarashi, J.D. Engel, and M. Yamamoto Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain Genes Dev. 13 1999 76 86
3. D.D. Zhang, S.C. Lo, J.V. Cross, D.J. Templeton, and M. Hannink Keap1 is a redox-regulated substrate adaptor protein for a Cul3-dependent ubiquitin ligase complex Mol. Cell. Biol. 24 2004 10941 10953
4. W.O. Osburn, and T.W. Kensler Nrf2 signaling: an adaptive response pathway for protection against environmental toxic insults Mutat. Res. 659 2008 31 39
5. K. Chan, X.D. Han, and Y.W. Kan An important function of Nrf2 in combating oxidative stress: detoxification of acetaminophen Proc. Natl. Acad. Sci. USA 98 2001 4611 4616
6. A. Enomoto, K. Itoh, E. Nagayoshi, J. Haruta, T. Kimura, T. O'Connor, T. Harada, and M. Yamamoto High sensitivity of Nrf2 knockout mice to acetaminophen hepatotoxicity associated with decreased expression of ARE-regulated drug metabolizing enzymes and antioxidant genes Toxicol. Sci. 59 2001 169 177
7. L.M. Aleksunes, M.J. Goedken, C.E. Rockwell, J. Thomale, J.E. Manautou, and C.D. Klaassen Transcriptional regulation of renal cytoprotective genes by Nrf2 and its potential use as a therapeutic target to mitigate cisplatin-induced nephrotoxicity J. Pharmacol. Exp. Ther. 335 2010 2 12
8. H.Y. Cho, S.P. Reddy, M. Yamamoto, and S.R. Kleeberger The transcription factor NRF2 protects against pulmonary fibrosis FASEB J 18 2004 1258 1260
9. H. Okawa, H. Motohashi, A. Kobayashi, H. Aburatani, T.W. Kensler, and M. Yamamoto Hepatocyte-specific deletion of the Keap1 gene activates Nrf2 and confers potent resistance against acute drug toxicity Biochem. Biophys. Res. Commun. 339 2006 79 88
10. K. Taguchi, H. Motohashi, and M. Yamamoto Molecular mechanisms of the Keap1-Nrf2 pathway in stress response and cancer evolution Genes Cells 16 2011 123 140
11. S.L. Slocum, and T.W. Kensler Nrf2: control of sensitivity to carcinogens Arch. Toxicol. 85 2011 273 284
12. D. Ren, N.F. Villeneuve, T. Jiang, T. Wu, A. Lau, H.A. Toppin, and D.D. Zhang Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism Proc. Natl. Acad. Sci. USA 108 2011 1433 1438
13. T. Wu, B.G. Harder, P.K. Wong, J.E. Lang, and D.D. Zhang Oxidative stress, mammospheres and Nrf2 - new implication for breast cancer therapy? Mol. Carcinog. 2014 (in press)
14. S. Tao, S. Wang, S.J. Moghaddam, A. Ooi, E. Chapman, P.K. Wong, and D.D. Zhang Oncogenic KRAS confers chemoresistance by upregulating NRF2 Cancer Res. 2014 (in press)
15. M. Darnell, M. Ulvestad, E. Ellis, L. Weidolf, and T.B. Andersson In vitro evaluation of major in vivo drug metabolic pathways using primary human hepatocytes and HepaRG cells in suspension and a dynamic three-dimensional bioreactor system J. Pharmacol. Exp. Ther. 343 2012 134 144
16. A. Lister, T. Nedjadi, N.R. Kitteringham, F. Campbell, E. Costello, B. Lloyd, I.M. Copple, S. Williams, A. Owen, J.P. Neoptolemos, C.E. Goldring, and B.K. Park Nrf2 is overexpressed in pancreatic cancer: implications for cell proliferation and therapy Mol. Cancer 10 2011 37
17. W. Willingham Jr, E.A. Stafford, S.H. Reynolds, S.G. Chaney, K.H. Lee, M. Okano, and I.H. Hall Mechanism of eukaryotic protein synthesis inhibition by brusatol Biochim. Biophys. Acta 654 1981 169 174
18. W. Willingham 3rd, R.T. Considine, S.G. Chaney, K.H. Lee, and I.H. Hall Reversibility of protein synthesis inhibition by quassinoid antineoplastic agents in a rabbit reticulocyte system Biochem. Pharmacol. 33 1984 330 333
19. T. Nguyen, P.J. Sherratt, H.C. Huang, C.S. Yang, and C.B. Pickett Increased protein stability as a mechanism that enhances Nrf2-mediated transcriptional activation of the antioxidant response element: degradation of Nrf2 by the 26 S proteasome J. Biol. Chem. 278 2003 4536 4541
20. I.P. Nezis, and H. Stenmark p62 at the interface of autophagy, oxidative stress signaling, and cancer Antioxid. Redox Signaling 17 2012 786 793
21. G. Bjorkoy, T. Lamark, S. Pankiv, A. Overvatn, A. Brech, and T. Johansen Monitoring autophagic degradation of p62/SQSTM1 Methods Enzymol. 452 2009 181 197
22. I.M. Copple The Keap1-Nrf2 cell defense pathway - a promising therapeutic target? Adv. Pharmacol. 63 2012 43 79
23. M. Landriscina, F. Maddalena, G. Laudiero, and F. Esposito Adaptation to oxidative stress, chemoresistance, and cell survival Antioxid. Redox Signaling 11 2009 2701 2716
24. O. Perez-Leal, C.A. Barrero, and S. Merali Translational control of Nrf2 within the open reading frame Biochem. Biophys. Res. Commun. 437 2013 134 139
25. X.J. Wang, J.D. Hayes, C.J. Henderson, and C.R. Wolf Identification of retinoic acid as an inhibitor of transcription factor Nrf2 through activation of retinoic acid receptor alpha Proc. Natl. Acad. Sci. USA 104 2007 19589 19594
26. X. Tang, H. Wang, L. Fan, X. Wu, A. Xin, H. Ren, and X.J. Wang Luteolin inhibits Nrf2 leading to negative regulation of the Nrf2/ARE pathway and sensitization of human lung carcinoma A549 cells to therapeutic drugs Free Radic. Biol. Med. 50 2011 1599 1609
27. A. Arlt, S. Sebens, S. Krebs, C. Geismann, M. Grossmann, M.L. Kruse, S. Schreiber, and H. Schafer Inhibition of the Nrf2 transcription factor by the alkaloid trigonelline renders pancreatic cancer cells more susceptible to apoptosis through decreased proteasomal gene expression and proteasome activity Oncogene 32 2013 4825 4835